Patriot Financial Group Insurance Agency, LLC Altimmune, Inc. Transaction History

Patriot Financial Group Insurance Agency, LLC

$704 Million
Q4 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 10, 2022	SELL	$8.69 - $12.48 $4,345 - $6,240	-500 Closed	0 $0
Q3 2021 Nov 24, 2021	SELL	$8.43 - $16.81 $24,025 - $47,908	-2,850 Reduced 85.07%	500 $6,000
Q2 2021 Jul 30, 2021	SELL	$9.85 - $16.46 $69,935 - $116,866	-7,100 Reduced 67.94%	3,350 $33,000
Q1 2021 Apr 29, 2021	BUY	$12.71 - $24.31 $19,700 - $37,680	1,550 Added 17.42%	10,450 $148,000
Q4 2020 Jan 15, 2021	BUY	$7.84 - $14.22 $69,776 - $126,558	8,900 New	8,900 $100,000

Others Institutions Holding ALT

# of Institutions

208

Shares Held

39.5M

Call Options Held

1.94M

Put Options Held

1.38M

Black Rock Inc. New York, NY

5.32M
Shares

$34.2 Million
0.0% of portfolio
Ameriprise Financial Inc Minneapolis, MN

5.25M
Shares

$33.8 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

4.43M
Shares

$28.5 Million
0.0% of portfolio
State Street Corp Boston, MA

3.47M
Shares

$22.3 Million
0.0% of portfolio
Tang Capital Management LLC San Diego, CA

2.75M
Shares

$17.7 Million
1.49% of portfolio

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $315M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Patriot Financial Group Insurance Agency, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Patriot Financial Group Insurance Agency, LLC with notifications on news.

Account